{"id":760454,"date":"2023-05-25T08:04:23","date_gmt":"2023-05-25T12:04:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/"},"modified":"2023-05-25T08:04:23","modified_gmt":"2023-05-25T12:04:23","slug":"spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/","title":{"rendered":"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors"},"content":{"rendered":"

<\/p>\n

Spruce Biosciences<\/b>Appoints Percival Barretto-Ko to Board of Directors<\/b><\/p>\n

Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board<\/i><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Spruce Biosciences, Inc<\/a>. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company\u2019s Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors.<\/p>\n

\n\u201cOn behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors,\u201d said Mike Grey, Executive Chairman of Spruce Biosciences. \u201cPercival is an accomplished and highly respected biopharmaceutical leader with deep commercial expertise who joins a Board of industry experts that share a conviction around the potential of tildacerfont to alter the course of management for people living with congenital adrenal hyperplasia (CAH) and other rare endocrine disorders. Percival\u2019s global experience and insights will be invaluable as we prepare for the potential commercialization of tildacerfont.\u201d<\/p>\n

\nMr. Grey added, \u201cWe are also grateful to Dina for her vast contributions to the Board over the past three years. Her counsel and support have helped guide and advance Spruce\u2019s pipeline from early proof-of-concept to late-stage clinical development.\u201d<\/p>\n

\nMr. Barretto-Ko is a life sciences industry veteran with over 20 years of commercial expertise and biopharmaceutical experience across various therapeutic focuses. Most recently, he has served as President and Chief Executive Officer at Plexium, Inc. Prior to joining Plexium, Mr. Barretto-Ko served in numerous roles at Astellas Pharma Inc., including the Chief Business Officer and President of Astellas Pharma US, from 2005 to 2021. Prior to joining Astellas, Mr. Barretto-Ko served in increasingly senior roles at Roche UK and US from 2001 to 2005. Mr. Barretto-Ko earned his B.S. in Biological Sciences and Chemistry with Honors from Cornell University and an M.B.A. from Yale University. In addition, he served as a Sloan Fellow for Innovation and Global Leadership at the MIT Sloan School of Management, where he was awarded an M.S. degree in Management. Mr. Barretto-Ko is a board member of Alessa Therapeutics, Inc., a pharmaceutical company, and Americares, a health-focused relief and development organization that serves people affected by poverty or disaster with life-changing medicine and health programs.<\/p>\n

\n\u201cI am impressed by the progress Spruce has made in advancing tildacerfont across multiple clinical programs to potentially change the treatment paradigm for patients with classic CAH and polycystic ovary syndrome,\u201d said Percival Barretto-Ko. \u201cThis is an incredibly exciting time for the company, and with an outstanding board and management team at the helm, I look forward to contributing my global experience to support our efforts in developing and commercializing potentially groundbreaking therapies to treat pediatric and adult patients with rare endocrine disorders.\u201d<\/p>\n

About Spruce Biosciences<\/b><\/p>\n

\nSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com<\/a> and follow us on Twitter @Spruce_Bio<\/a>, LinkedIn<\/a>, Facebook<\/a> and YouTube<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nStatements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential of tildacerfont to alter the course of management for people living with CAH and the potential commercialization of tildacerfont. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as \u201cforward,\u201d \u201cwill,\u201d \u201cpotential\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce\u2019s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce\u2019s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management\u2019s assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230525005326\/en\/<\/a><\/span><\/p>\n

Media
\n<\/b>
Will Zasadny
\n
Evoke Canale
\n
(619) 961-8848
\n
will.zasadny@evokecanale.com
\n<\/a>
media@sprucebiosciences.com<\/a><\/p>\n

Investors
\n<\/b>
Xuan Yang
\n
Solebury Strategic Communications
\n
(415) 971-9412
\n
xyang@soleburystrat.com
\n<\/a>
investors@sprucebiosciences.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Health Genetics Pharmaceutical Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company\u2019s Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. \u201cOn behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors,\u201d said Mike Grey, Executive Chairman of Spruce Biosciences. \u201cPercival is an accomplished and highly respected biopharmaceutical leader with deep commercial expertise who joins a … <\/p>\n

Continue reading “Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-760454","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSpruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company\u2019s Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. \u201cOn behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors,\u201d said Mike Grey, Executive Chairman of Spruce Biosciences. \u201cPercival is an accomplished and highly respected biopharmaceutical leader with deep commercial expertise who joins a … Continue reading "Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-25T12:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors\",\"datePublished\":\"2023-05-25T12:04:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/\"},\"wordCount\":856,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/\",\"name\":\"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-25T12:04:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors - Market Newsdesk","og_description":"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company\u2019s Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. \u201cOn behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors,\u201d said Mike Grey, Executive Chairman of Spruce Biosciences. \u201cPercival is an accomplished and highly respected biopharmaceutical leader with deep commercial expertise who joins a … Continue reading \"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-25T12:04:23+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors","datePublished":"2023-05-25T12:04:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/"},"wordCount":856,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/","name":"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-25T12:04:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230525005326r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spruce-biosciencesappoints-percival-barretto-ko-to-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spruce BiosciencesAppoints Percival Barretto-Ko to Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=760454"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/760454\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=760454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=760454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=760454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}